To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Madrigal Pharmaceuticals is ...

Madrigal Pharmaceuticals (MDGL) is back on investors radar after Rezdiffra s early launch exceeded expectations, putting the MASH therapy on a path toward blockbuster level sales and reshaping the ...

In November 2025, Madrigal Pharmaceuticals announced positive two-year results from the open-label compensated MASH cirrhosis arm of its Phase 3 MAESTRO-NAFLD-1 trial, showing statistically ...

Madrigal (shoulder) cleared waivers and opted for free agency Thursday. Madrigal missed the full 2025 campaign after undergoing surgery in February to repair a fractured left shoulder. The infielder, ...

Shares of Madrigal Pharmaceuticals (MDGL) traded sharply higher for the second straight session on Wednesday after Cantor Fitzgerald upgraded the company, arguing that the commercial rollout of its ...

Madrigal Pharmaceuticals is reiterated as a Strong Buy, driven by Rezdiffra's rapid US launch and recent European approval. Q2 2025 saw Rezdiffra sales reach $213M and >23,000 patients, with Q3 ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

The Giants have informed other teams that they’ll listen to offers on some of their bullpen, reports Jon Morosi of MLB Network. Francys Romero reports that Camilo Doval, in particular, has drawn ...

July 30 (Reuters) - U.S. drugmaker Madrigal Pharmaceuticals (MDGL.O), opens new tab has struck a licensing deal with CSPC Pharmaceutical Group (1093.HK), opens new tab that could be worth more than $2 ...

Madrigal Pharmaceuticals is paying $120 million upfront for a preclinical GLP-1 receptor agonist that the biopharma plans to pair up with its approved fatty liver disease med Rezdiffra. The GLP-1 drug ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Madrigal Pharmaceuticals inks $2 ...

The San Francisco Giants have put together one of baseball’s most dominant bullpens. They ranked second in the majors in ERA (3.23), third in opponents’ OPS (.643) and first in WHIP (1.16), led by ...